DE60115464T2 - Testosteron-ester formulierung zur anwendung am menschen - Google Patents

Testosteron-ester formulierung zur anwendung am menschen Download PDF

Info

Publication number
DE60115464T2
DE60115464T2 DE60115464T DE60115464T DE60115464T2 DE 60115464 T2 DE60115464 T2 DE 60115464T2 DE 60115464 T DE60115464 T DE 60115464T DE 60115464 T DE60115464 T DE 60115464T DE 60115464 T2 DE60115464 T2 DE 60115464T2
Authority
DE
Germany
Prior art keywords
testosterone
people
testosterone ester
formulation
ester formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60115464T
Other languages
English (en)
Other versions
DE60115464D1 (de
Inventor
Nijs Henrik De
Margaretha Kersemaekers
Cornelis Schutte
Bruggen Gerhard Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of DE60115464D1 publication Critical patent/DE60115464D1/de
Application granted granted Critical
Publication of DE60115464T2 publication Critical patent/DE60115464T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60115464T 2000-08-23 2001-08-17 Testosteron-ester formulierung zur anwendung am menschen Expired - Fee Related DE60115464T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202939 2000-08-23
PCT/EP2001/009569 WO2002015938A2 (en) 2000-08-23 2001-08-17 Testosterone ester formulation for human use

Publications (2)

Publication Number Publication Date
DE60115464D1 DE60115464D1 (de) 2006-01-05
DE60115464T2 true DE60115464T2 (de) 2006-06-14

Family

ID=8171940

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60115464T Expired - Fee Related DE60115464T2 (de) 2000-08-23 2001-08-17 Testosteron-ester formulierung zur anwendung am menschen

Country Status (15)

Country Link
US (1) US20050101517A1 (de)
EP (1) EP1313511B1 (de)
JP (1) JP2004506698A (de)
CN (1) CN1248738C (de)
AT (1) ATE311201T1 (de)
AU (2) AU2001291775B2 (de)
BR (1) BR0113376A (de)
CA (1) CA2415349A1 (de)
CY (1) CY1106064T1 (de)
DE (1) DE60115464T2 (de)
DK (1) DK1313511T3 (de)
ES (1) ES2253423T3 (de)
IL (2) IL153648A0 (de)
MX (1) MXPA03001147A (de)
WO (1) WO2002015938A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
JO2505B1 (en) 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
IL157535A0 (en) * 2003-08-21 2004-03-28 Topimed Ltd Preparations for the prevention of skin atrophy
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP2452670A1 (de) * 2004-10-01 2012-05-16 Ramscor, Inc. Einfach implantierbare Arzneimittelzusammensetzungen mit verzögerter Freisetzung
DK2985026T3 (da) 2005-04-15 2022-10-31 Clarus Therapeutics Inc Farmaceutiske leveringssystemer til hydrofobe lægemidler og sammensætninger dermed
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
CA2822435C (en) * 2009-12-31 2018-09-11 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN105188670B (zh) 2013-03-15 2018-11-02 马留斯医药有限责任公司 乳液制剂
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
WO2015100406A1 (en) 2013-12-26 2015-07-02 Clarus Therapeutics, Inc. Use of oral pharmaceutical products combining testosterone esters with hypolipidemic agents
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US10188602B2 (en) 2016-09-29 2019-01-29 Gesea Biosciences Inc. Bioerodible implant for long-term drug delivery and associated methods of manufacture and use
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB465331A (en) * 1935-10-05 1937-05-05 Chem Ind Basel Manufacture of new esters of polynuclear cyclic oxyketones
NL189235C (nl) * 1974-02-28 1993-02-16 Akzo Nv Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking.
US4098802A (en) * 1975-02-18 1978-07-04 Akzona Incorporated Oral pharmaceutical preparation having androgenic activity
US4147783A (en) * 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
NL7506407A (nl) * 1975-05-30 1976-12-02 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
GB1567515A (en) * 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
ES2054784T3 (es) * 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
US7025979B2 (en) * 2000-02-15 2006-04-11 Schering Ag Male contraceptive formulation comprising norethisterone

Also Published As

Publication number Publication date
US20050101517A1 (en) 2005-05-12
MXPA03001147A (es) 2003-10-06
AU9177501A (en) 2002-03-04
EP1313511B1 (de) 2005-11-30
ES2253423T3 (es) 2006-06-01
ATE311201T1 (de) 2005-12-15
BR0113376A (pt) 2003-07-15
AU2001291775B2 (en) 2005-09-08
WO2002015938A3 (en) 2002-08-15
DE60115464D1 (de) 2006-01-05
IL153648A0 (en) 2003-07-06
CY1106064T1 (el) 2011-06-08
DK1313511T3 (da) 2006-03-20
IL153648A (en) 2009-02-11
WO2002015938A2 (en) 2002-02-28
WO2002015938A8 (en) 2004-03-04
EP1313511A2 (de) 2003-05-28
CN1443078A (zh) 2003-09-17
JP2004506698A (ja) 2004-03-04
CN1248738C (zh) 2006-04-05
CA2415349A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
DE60115464D1 (de) Testosteron-ester formulierung zur anwendung am menschen
ATE367087T1 (de) Formulierungen zur behandlung von krankheiten und verfahren unter deren verwendung
AU2001249360A1 (en) Low fat nut spread composition with high protein and fiber
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
MY138883A (en) Use of asiatic acid for treatment of cencer
AU2002345255A1 (en) Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
CL2004000026A1 (es) Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.
ATE314084T1 (de) Kahalalid f formulierung
CA2216887A1 (en) Budesonide alone or in combination with ursodeoxycholic acid in the therapy of cholestatic liver diseases
NO20023102L (no) Fremgangsmåte og formulering for behandling av residens mot anti-hypertensiver og relaterte tilstander
BR0210101A (pt) Combinações antineoplásticas
DE60021590D1 (de) Verwendung von baclofen zur behandlung von alkoholismus
AU2001265186A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
ATA18952001A (de) Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
WO2001085188A3 (en) Use of echinacea as a hematinic agent
DE60137082D1 (de) Zusammensetzungen von arginin mit kontrollierter freigabe
DE59911381D1 (de) Verwendung von testosteronestern und/oder testosteron zur herstellung von bukkal applizierbaren bioadhasiven systemen mit zeitgesteuerter arzneistoffwirkung
FR2812549B1 (fr) Associations dalfopristine/quinupristine avec le cefpirome
NZ504525A (en) Use of cetyl alcohol esters of myristic and palmitic acids to treat eczema and psoriasis
BG107240U (en) Applicator

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: N.V. ORGANON, OSS, NL

8339 Ceased/non-payment of the annual fee